Novo Nordisk said on Friday its experimental next-generation obesity drug CagriSema helped overweight patients cut their weight by 22.7 percent in a late-stage trial, below the 25 percent it had expected, sending its shares down sharply.
The lower-than-expected weight loss from the drug candidate deals a blow to the Danish drugmaker’s ambitions for a successor to its popular Wegovy more powerful than Eli Lilly’s Zepbound.
